Cognitive impairments from developmental exposure to serotonergic drugs: citalopram and MDMA
Tori L. Schaefer, Curtis E. Grace, A Braun, Robyn M. Amos‐kroohs, Devon L. Graham, Matthew R. Skelton, Michael T. Williams, Charles V. Vorhees
The International Journal of Neuropsychopharmacology January 11, 2013 DOI: 10.1017/s1461145712001447 via OpenAlex
Summary
AI-generated from the abstractIn rats, treatment with the recreational drug MDMA during a developmental period equivalent to the human third trimester causes long-term spatial and egocentric learning and memory deficits, along with serotonin reductions. Pretreatment with the antidepressant citalopram, a selective serotonin reuptake inhibitor, did not prevent these cognitive deficits. Unexpectedly, citalopram alone produced learning deficits as severe as those caused by MDMA. These are the first findings showing cognitive impairments from developmental exposure to a selective serotonin reuptake inhibitor, suggesting the need for further research on the long-term safety of antidepressants during pregnancy.
Study at a glance
| Characteristics | Controlled experiment Peer reviewed |
|---|---|
| Population | Rat pups treated on postnatal days 11-20 |
| Interventions | MDMA Citalopram |
| Dose | 10 mg/kg × 4/d at 2 h intervals for MDMA; 5 or 7.5 mg/kg × 2/d for citalopram |
| Topics | MDMA Serotonin |
| Keywords | Citalopram Psychology Serotonin reuptake inhibitor |
| Citations | 24 |
| Key finding | Citalopram pretreatment did not attenuate MDMA-induced cognitive deficits, and citalopram alone caused learning deficits as severe as MDMA. |
Abstract
Abstract We previously showed that developmental 3,4-methylenedioxymethamphetamine (MDMA) treatment induces long-term spatial and egocentric learning and memory deficits and serotonin (5-HT) reductions. During brain development, 5-HT is a neurotrophic factor influencing neurogenesis, synaptogenesis, migration, and target field organization. MDMA (10 mg/kg × 4/d at 2 h intervals) given on post-natal day (PD) 11–20 in rats (a period of limbic system development that approximates human third trimester brain development) induces 50% reductions in 5-HT during treatment and 20% reductions when assessed as adults. To determine whether the 5-HT reduction is responsible for the cognitive deficits, we used citalopram (Cit) pretreatment to inhibit the effects of MDMA on 5-HT reuptake in a companion study. Cit attenuated MDMA-induced 5-HT reductions by 50% (Schaefer et al., 2012). Here we tested whether Cit (5 or 7.5 mg/kg × 2/d) pretreatment attenuates the cognitive effects of MDMA. Within each litter, different offspring were treated on PD11–20 with saline (Sal) + MDMA, Cit + MDMA, Cit + Sal or Sal + Sal. Neither spatial nor egocentric learning/memory was improved by Cit pretreatment. Unexpectedly, Cit + Sal (at both doses) produced spatial and egocentric learning deficits as severe as those caused by Sal + MDMA. These are the first data showing cognitive deficits resulting from developmental exposure to a selective serotonin reuptake inhibitor. These data indicate the need for further research on the long-term safety of antidepressants during pregnancy.